222 related articles for article (PubMed ID: 30149884)
21. The Effectiveness of Afatinib in a Patient with Advanced Lung Adenocarcinoma Harboring Rare G719X and S768I Mutations.
Watanabe M; Oizumi S; Kiuchi S; Yamada N; Yokouchi H; Fukumoto S; Harada M
Intern Med; 2018 Apr; 57(7):993-996. PubMed ID: 29225262
[TBL] [Abstract][Full Text] [Related]
22. Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases.
Li SH; Liu CY; Hsu PC; Fang YF; Wang CC; Kao KC; Tseng LC; Yang CT
Expert Rev Anticancer Ther; 2018 Jan; 18(1):81-89. PubMed ID: 29172778
[TBL] [Abstract][Full Text] [Related]
23. Phase II study of the multitargeted tyrosine kinase inhibitor XL647 in patients with non-small-cell lung cancer.
Pietanza MC; Gadgeel SM; Dowlati A; Lynch TJ; Salgia R; Rowland KM; Wertheim MS; Price KA; Riely GJ; Azzoli CG; Miller VA; Krug LM; Kris MG; Beumer JH; Tonda M; Mitchell B; Rizvi NA
J Thorac Oncol; 2012 May; 7(5):856-65. PubMed ID: 22722787
[TBL] [Abstract][Full Text] [Related]
24. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.
De Grève J; Teugels E; Geers C; Decoster L; Galdermans D; De Mey J; Everaert H; Umelo I; In't Veld P; Schallier D
Lung Cancer; 2012 Apr; 76(1):123-7. PubMed ID: 22325357
[TBL] [Abstract][Full Text] [Related]
25. Comparing the effects of afatinib with gefitinib or Erlotinib in patients with advanced-stage lung adenocarcinoma harboring non-classical epidermal growth factor receptor mutations.
Shen YC; Tseng GC; Tu CY; Chen WC; Liao WC; Chen WC; Li CH; Chen HJ; Hsia TC
Lung Cancer; 2017 Aug; 110():56-62. PubMed ID: 28676220
[TBL] [Abstract][Full Text] [Related]
26. The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung Adenocarcinoma harboring exon 19 or exon 21 mutations.
Yang CJ; Tsai MJ; Hung JY; Lee MH; Tsai YM; Tsai YC; Hsu JF; Liu TC; Huang MS; Chong IW
BMC Pharmacol Toxicol; 2017 Dec; 18(1):82. PubMed ID: 29237484
[TBL] [Abstract][Full Text] [Related]
27. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
[TBL] [Abstract][Full Text] [Related]
28. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
29. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
Nagasaka M; Singh V; Baca Y; Sukari A; Kim C; Mamdani H; Spira AI; Uprety D; Bepler G; Kim ES; Raez LE; Pai SG; Ikpeazu C; Oberley M; Feldman R; Xiu J; Korn WM; Wozniak AJ; Borghaei H; Liu SV
Clin Lung Cancer; 2022 Jan; 23(1):52-59. PubMed ID: 34801409
[TBL] [Abstract][Full Text] [Related]
30. Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
Landi L; Tiseo M; Chiari R; Ricciardi S; Rossi E; Galetta D; Novello S; Milella M; D'Incecco A; Minuti G; Tibaldi C; Salvini J; Facchinetti F; Haspinger ER; Cortinovis D; Santo A; Banna G; Catino A; GiajLevra M; Crinò L; de Marinis F; Cappuzzo F
Clin Lung Cancer; 2014 Nov; 15(6):411-417.e4. PubMed ID: 25242668
[TBL] [Abstract][Full Text] [Related]
31. Afatinib combined with anlotinib in the treatment of lung adenocarcinoma patient with novel HER2 mutation: a case report and review of the literature.
Xu H; Liang Q; Xu X; Tan S; Wang S; Liu Y; Liu L
World J Surg Oncol; 2021 Nov; 19(1):330. PubMed ID: 34794435
[TBL] [Abstract][Full Text] [Related]
32. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.
Katakami N; Atagi S; Goto K; Hida T; Horai T; Inoue A; Ichinose Y; Koboyashi K; Takeda K; Kiura K; Nishio K; Seki Y; Ebisawa R; Shahidi M; Yamamoto N
J Clin Oncol; 2013 Sep; 31(27):3335-41. PubMed ID: 23816963
[TBL] [Abstract][Full Text] [Related]
33. Phase II study of afatinib, an irreversible ErbB family blocker, in EGFR FISH-positive non-small-cell lung cancer.
Cappuzzo F; Finocchiaro G; Grossi F; Bidoli P; Favaretto A; Marchetti A; Valente ML; Cseh A; Clementi L; Massey D; Santoro A
J Thorac Oncol; 2015 Apr; 10(4):665-72. PubMed ID: 25514804
[TBL] [Abstract][Full Text] [Related]
34. HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.
Wang Y; Jiang T; Qin Z; Jiang J; Wang Q; Yang S; Rivard C; Gao G; Ng TL; Tu MM; Yu H; Ji H; Zhou C; Ren S; Zhang J; Bunn P; Doebele RC; Camidge DR; Hirsch FR
Ann Oncol; 2019 Mar; 30(3):447-455. PubMed ID: 30596880
[TBL] [Abstract][Full Text] [Related]
35. Real World Characteristics and Clinical Outcomes of HER2-Mutant Non-Small Cell Lung Cancer Patients Detected by Next-Generation Sequencing.
Ahn BC; Han YJ; Kim HR; Hong MH; Cho BC; Lim SM
Cancer Res Treat; 2023 Apr; 55(2):488-497. PubMed ID: 36397236
[TBL] [Abstract][Full Text] [Related]
36. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
[TBL] [Abstract][Full Text] [Related]
37. Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients.
Kim JY; Lee E; Park K; Jung HH; Park WY; Lee KH; Sohn J; Lee KS; Jung KH; Kim JH; Lee KH; Im SA; Park YH
Int J Cancer; 2019 Sep; 145(6):1669-1678. PubMed ID: 30720867
[TBL] [Abstract][Full Text] [Related]
38. Afatinib successfully treated leptomeningeal metastasis during erlotinib treatment in a patient with EGFR-mutant (Exon18:G719S) lung adenocarcinoma as a second-line chemotherapy.
Tamiya M; Shiroyama T; Nishihara T; Nishida T; Hayama M; Tanaka A; Morishita N; Suzuki H; Okamoto N; Hirashima T
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e531-e533. PubMed ID: 28004883
[TBL] [Abstract][Full Text] [Related]
39. Prognostic and predictive implications of HER2/ERBB2/neu gene mutations in lung cancers.
Tomizawa K; Suda K; Onozato R; Kosaka T; Endoh H; Sekido Y; Shigematsu H; Kuwano H; Yatabe Y; Mitsudomi T
Lung Cancer; 2011 Oct; 74(1):139-44. PubMed ID: 21353324
[TBL] [Abstract][Full Text] [Related]
40. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
